DENVER, Colo., Nov 14, 2023 (www.247marketnews.com)- INVO Bioscience, Inc. (NASDAQ: INVO) reported, after yesterday’s market close, its third quarter financial results and stated that it expects to host a call concerning its NAYA definitive merger agreement, after November 20th. Its revenues increased 314%, from $235,321 to $974,894 and, assuming a full quarter of the recently acquired Wisconsin Fertility Institute, pro forma revenue for Q3 2023 would have been approximately $1.5 million.
INVO Bioscience is trading at $2.11, up $0.50 (+31.1%) on 990.4K premarket shares.
Its 52-week range is $0.50 to $25.398. It’s positioned to challenge its October 23 trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
